- Interim data from a Phase 2 trial assessing Galena Biopharma's (GALE) anagrelide controlled release (GALE-401) in patients with thrombocytosis secondary to essential thrombocythemia (ET) and other myeloproliferative neoplasms (MPNs) show encouraging efficacy. The data were presented at the 20th Congress of the European Hematology Association in Vienna, Austria.
- The overall response rate in the 18-subject study was 78% (n=14/18) and complete and partial response rates were both 39% (n=7/18). The median time to response was five weeks (range: 3-10) while the median duration of response had not been reached by the data cutoff.
-
Thrombocytosis is a disorder in which the body produces too many platelets.
- The immediate release formulation of anagrelide, Agrylin, was approved in 1997 for the indication.
- Final data from the trial will be presented at the American Society of Hematology meeting in December.